risk; pediatric patients in the prevention of CMV disease in kidney
or heart transplant patients at high risk.
Roche’s Valcyte is also available as an oral solution (50 mg/mL).
Hovione Files IND for Topical Minocycline
Hovione has announced that it has filed an Investigational New
Drug (IND) Application with the FDA for minocycline gel, a
novel formulation to administer topically using a new patented
crystalline base form of minocycline, one of the most widely
prescribed oral antibiotics for acne. Pending FDA’s acceptance
of the IND submission, Hovione plans to initiate human clinical
Phase 1/2 studies in early 2015.
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from FDA
Bristol-Myers Squibb Company has announced that the FDA
approved Opdivo (nivolumab) injection, for intravenous
use. Opdivo is a human programmed death receptor-1 (PD-
1) blocking antibody indicated for the treatment of patients
with unresectable or metastatic melanoma and disease progression
following Yervoy (ipilimumab) and, if BRAF V600
mutation positive, a BRAF inhibitor. This indication is approved
under accelerated approval based on tumor response
rate and durability of response. Continued approval for this
indication may be contingent upon verification and description
of clinical benefit in the confirmatory trials.
Opdivo demonstrated efficacy in a Phase 3, pivotal clinical
trial with advanced melanoma in patients who had been
previously treated and progressed with Yervoy and, if BRAF
mutation positive, a BRAF inhibitor. The efficacy of Opdivo
was evaluated based on a single-arm, non-comparative
planned interim analysis of the first 120 patients who received
Opdivo with a minimum of 6 months follow-up in the
Phase 3 CheckMate -037 trial.
Opdivo achieved a 32% (95% CI: 23, 41) response rate (38/120)
with a dosing strength and frequency of 3 mg/kg intravenously
over 60 minutes every 2 weeks. 3% of patients (4/120)
achieved a complete response, and 28% (34/120) achieved a
partial response. Of 38 patients with responses, 33 patients
(87%) had ongoing responses with durability of response
ranging from 2.6+ to 10+ months, which included 13 patients
with ongoing responses of 6 months or longer. Responses to
Opdivo were demonstrated in both patients with and without
BRAF mutation.
The safety profile of Opdivo has been demonstrated in the pivotal,
Phase 3 CheckMate-037 trial. Serious adverse reactions
occurred in 41% of patients receiving Opdivo. Grade 3 and 4 adverse
reactions occurred in 42% of patients receiving Opdivo.
The most frequent Grade 3 and 4 adverse drug reactions reported
in 2% to <5% of patients receiving Opdivo were abdominal pain, hyponatremia, increased aspartate aminotransferase, and
increased lipase. The most common adverse reaction (≥20%)
reported with Opdivo was rash (21%).
CheckMate -037 was a randomized, Phase 3 trial evaluating
Opdivo 3 mg/kg (n=268), administered every two weeks,
or chemotherapy (n=102) (investigator's choice of either
single-agent dacarbazine 1000 mg/m2 every 3 weeks or the
combination of carboplatin AUC 6 every 3 weeks plus paclitaxel
175 mg/m2 every 3 weeks) in patients with advanced
melanoma who had been previously treated and progressed
with Yervoy and, if BRAF mutation positive, a BRAF inhibitor.
No premedication is required with Opdivo.
The primary objective of this analysis of the CheckMate -037
trial was Objective Response Rate (ORR). CheckMate -037 included
90 participating trial sites in 14 countries, and included
both institutional and community practice centers. The clinical
study is ongoing to determine whether there is an overall
survival benefit.
In the Opdivo treated patients (n=120), 76% of patients had
M1C disease, 18% of patients had a history of brain metastases,
and 56% of patients had elevated LDH levels. The
median age of patients was 58. 22% of patients were BRAF
V600 mutation positive.